title: Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A2B and A3 adenosine receptors.
abstract: Adenosine is released during tissue injury, ischemia and tumor growth, and promotes angiogenesis. Because mast cells accumulate in the proximity of new blood vessel development, we examined if they may contribute to adenosine-induced angiogenesis. We found that HMC-1 human mast cells express A2A, A2B, and A3 adenosine receptors. The adenosine agonist NECA (100 micromol/L) increased interleukin-8 (IL-8), vascular endothelial growth factor (VEGF), and angiopoietin-2 mRNA expression. NECA-induced secretion of IL-8 and VEGF was verified by ELISA. A2B receptors mediate VEGF and IL-8 secretion because neither CGS21680 (selective A2A agonist) nor IB-MECA (selective A3 agonist) produced this effect, and it was inhibited by the selective A2B antagonist IPDX but not by the selective A2A antagonist SCH58261 or the selective A3 antagonist MRS1191. In contrast, the selective A3 agonist IB-MECA (EC50 1 nmol/L) stimulated angiopoietin-2 expression. Conditioned media from NECA-activated HMC-1 stimulated human umbilical vein endothelial cell proliferation and migration, and induced capillary tube formation. Capillary formation induced by mast cell-conditioned media was maximal if both HMC-1 A2B and A3 receptors were activated, whereas activation of A2B receptor alone was less effective. Thus, adenosine A2B and A3 receptors act in a functional cooperative fashion to promote angiogenesis by a paracrine mechanism involving the differential expression and secretion of angiogenic factors from human mast cells.
authors.affiliation: Division of Cardiovascular Medicine, Vanderbilt University, Nashville, Tenn 37232-6300, USA. igor.feoktistov@mcmail.vanderbilt.edu
authors.forename: Igor
authors.initials: I
authors.lastname: Feoktistov
authors.forename: Sergey
authors.initials: S
authors.lastname: Ryzhov
authors.forename: Anna E
authors.initials: AE
authors.lastname: Goldstein
authors.forename: Italo
authors.initials: I
authors.lastname: Biaggioni
mesh_terms: D000241:Adenosine / Q000494:pharmacology; D043925:Angiogenesis Inducing Agents / Q000096:biosynthesis / Q000235:genetics; D042702:Angiopoietin-2; D002460:Cell Line; D017077:Culture Media, Conditioned / Q000494:pharmacology; D016228:Endothelial Growth Factors / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000096:biosynthesis / Q000235:genetics; D016209:Interleukin-8 / Q000096:biosynthesis; D008222:Lymphokines / Q000096:biosynthesis / Q000235:genetics; D008407:Mast Cells / Q000187:drug effects / Q000502:physiology*; D018919:Neovascularization, Physiologic; D019899:Paracrine Communication; D012333:RNA, Messenger / Q000096:biosynthesis; D043704:Receptor, Adenosine A2B; D043684:Receptor, Adenosine A3; D018047:Receptors, Purinergic P1 / Q000235:genetics / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D043925:Angiogenesis Inducing Agents; D042702:Angiopoietin-2; D017077:Culture Media, Conditioned; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D016209:Interleukin-8; D008222:Lymphokines; D012333:RNA, Messenger; D043704:Receptor, Adenosine A2B; D043684:Receptor, Adenosine A3; D018047:Receptors, Purinergic P1; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000241:Adenosine